Controlled-Release Oral Morphine (MS Contin Tablets, MSC) in Post-Operative Pain

1991 ◽  
Vol 7 (1) ◽  
pp. 41
Author(s):  
J. D. Brown ◽  
J. D. Van Wagoner ◽  
R. OʼCallaghan ◽  
R. F. Kaiko ◽  
R. P. Grandy ◽  
...  
Keyword(s):  
Controlled Release ◽  
Oral Morphine ◽  
Post Operative Pain

Controlled-release oral morphine (MS contin tablets, MSC) in postoperative pain

1990 ◽  
Vol 183 (4) ◽  
pp. 1437-1438
Author(s):  
R. Kaiko ◽  
J. Van Wagoner ◽  
J. Brown ◽  
V. O'Callaghan ◽  
R. Grandy ◽  
...  
Keyword(s):  
Controlled Release ◽  
Postoperative Pain ◽  
Oral Morphine

Steady-State Pharmacokinetics of Controlled Release Oral Morphine Sulphate in Healthy Subjects

1986 ◽  
Vol 11 (6) ◽  
pp. 505-510 ◽  
Author(s):  
John J. Savarese ◽  
Paul D. Goldenheim ◽  
Gordon B. Thomas ◽  
Robert F. Kaiko
Keyword(s):  
Steady State ◽  
Controlled Release ◽  
Healthy Subjects ◽  
Oral Morphine ◽  
Morphine Sulphate

scholarly journals Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management

2021 ◽  
Vol 329 ◽  
pp. 316-327
Author(s):  
Natasha C. Brigham ◽  
Rebecca Nofsinger ◽  
Xin Luo ◽  
Nathan Z. Dreger ◽  
Alexandra K. Abel ◽  
...  
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Post Operative Pain

Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation.

1987 ◽  
Vol 5 (6) ◽  
pp. 956-961 ◽  
Author(s):  
A Khojasteh ◽  
W Evans ◽  
R D Reynolds ◽  
G Thomas ◽  
J J Savarese
Keyword(s):  
Controlled Release ◽  
Side Effects ◽  
Cancer Patients ◽  
Peak Plasma ◽  
Oral Morphine ◽  
Extended Period ◽  
Morphine Sulfate ◽  
Control Group ◽  
Clinical Effects ◽  
The Mean

The bioavailability and clinical effects of an oral controlled-release morphine sulfate tablet, MS-contin (MSC; Purdue-Frederick, Norwalk, CT) in comparison to an immediate-release (IRMS) preparation were evaluated in normal subjects and cancer patients, respectively. The inherent slow-release character of MSC was confirmed by 2 1/2 X T1/2 absorption rate, one-half Cmax, and twice Tmax relative to IRMS. The T1/2 elimination of the two morphine preparations was similar, demonstrating insignificant risk of MSC accumulation. The difference in the mean number of side effects experienced by the control group per subject was significant (.70 for MSC and 1.26 for IRMS, P = .05) and was consistent with peak plasma morphine attenuation. The cancer patients were initially switched from their previous analgesic to four hourly IRMS and then to MSC at double the dose every eight hours. The majority had their MSC dosing interval lengthened to every 12 hours with a decrease in the total daily morphine requirement. While the mean duration on MSC was 20.5 days, many patients were followed poststudy for an extended period with no appreciable development of tolerance. Overall, MSC analgesia and side effects were perceived by the patients as superior compared with prestudy opioids. The advantage of less frequent dosing may lead to improvement of the quality of life of cancer patients.

Guidelines for use of controlled-release oral morphine in cancer pain management Correlation with clinical experience

1989 ◽  
Vol 12 (4) ◽  
pp. 202???208 ◽  
Author(s):  
Jeanne Lapin ◽  
Russell K. Portenoy ◽  
Nessa Coyle ◽  
Raymond W. Houde ◽  
Kathleen M. Foley
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Cancer Pain ◽  
Clinical Experience ◽  
Oral Morphine ◽  
Cancer Pain Management

scholarly journals A study of controlled-release oral morphine (Ms Contin) in an advanced cancer hospital

1987 ◽  
Vol 2 (4) ◽  
pp. 193-198 ◽  
Author(s):  
Frank J. Brescia ◽  
Monica Walsh ◽  
John J. Savarese ◽  
Robert F. Kaiko
Keyword(s):  
Controlled Release ◽  
Advanced Cancer ◽  
Oral Morphine ◽  
Cancer Hospital
Sign in / Sign up

Export Citation Format

Share Document